Independent Research set a €106.00 ($123.26) price objective on Merck KGaA (FRA:MRK) in a research report report published on Tuesday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other analysts also recently issued reports on MRK. JPMorgan Chase & Co. reiterated a neutral rating on shares of Merck KGaA in a report on Tuesday, January 15th. Barclays set a €78.00 ($90.70) price target on Merck KGaA and gave the company a sell rating in a report on Tuesday, January 15th. Nord/LB set a €80.00 ($93.02) price target on Merck KGaA and gave the company a sell rating in a report on Thursday, January 24th. Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the company a buy rating in a report on Thursday, January 24th. Finally, Sanford C. Bernstein set a €105.00 ($122.09) price target on Merck KGaA and gave the company a buy rating in a report on Tuesday, February 5th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of €101.35 ($117.85).
Shares of MRK opened at €91.62 ($106.53) on Tuesday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: Understanding Average Daily Trade Volume
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.